Suppr超能文献

低原始细胞 MDS 患者异基因移植后预处理强度对预后的影响:日本移植与细胞治疗学会成人 MDS 工作组的全国性回顾性研究。

Prognostic impact of the conditioning intensity on outcomes after allogeneic transplantation for MDS with low blasts: a nationwide retrospective study by the adult MDS working group of the Japan Society for Transplantation and Cellular Therapy.

机构信息

Transfusion and Cell Therapy Unit, Nagasaki University Hospital, Nagasaki, Japan.

Department of Hematology, Nagasaki University Hospital, Nagasaki, Japan.

出版信息

Bone Marrow Transplant. 2024 Aug;59(8):1107-1117. doi: 10.1038/s41409-024-02297-0. Epub 2024 May 7.

Abstract

Poor prognostic factors, such as transfusion dependency and chromosomal risk, need to be considered in the indication of allogeneic hematopoietic cell transplantation (allo-HCT) for patients harboring myelodysplastic syndromes with less than 5% marrow blasts (MDS-Lo). We analyzed the post-transplant outcomes of 1229 MDS-Lo patients who received myeloablative (MAC)(n = 651), reduced-intensity (RIC)(n = 397), and non-myeloablative conditioning (NMAC) regimens (n = 181). The multivariate analysis revealed that the RIC group had better chronic graft-versus-host disease (GVHD)- and relapse-free survival (CRFS) (P = 0.021), and GVHD- and relapse-free survival (GRFS) than the MAC group (P = 0.001), while no significant differences were observed between the NMAC and MAC groups. In the subgroup analysis, the MAC group has better overall survival (P = 0.008) than the RIC group among patients with an HCT-comorbidity index (HCT-CI) score of 0, while the RIC group had better overall survival (P = 0.029) than the MAC group among those with an HCT-CI score ≥3. According to the type of conditioning regimen, total body irradiation 12 Gy-based MAC regimen showed better OS and CRFS than the other MAC regimen, and comparable outcomes to the RIC regimen. In conclusion, the RIC and NMAC regimens are promising options for MDS-Lo patients in addition to the MAC regimen.

摘要

对于骨髓增生异常综合征(MDS)患者,如果骨髓原始细胞数<5%(MDS-Lo),并且存在输血依赖和染色体风险等不良预后因素,需要考虑行异基因造血细胞移植(allo-HCT)。我们分析了 1229 例接受清髓性(MAC)(n=651)、减低强度(RIC)(n=397)和非清髓性预处理(NMAC)(n=181)allo-HCT 的 MDS-Lo 患者的移植后结局。多变量分析显示,RIC 组慢性移植物抗宿主病(GVHD)-无复发存活率(CRFS)(P=0.021)和 GVHD-无复发存活率(GRFS)(P=0.001)优于 MAC 组,而 NMAC 组与 MAC 组之间无显著差异。在亚组分析中,在 HCT 合并症指数(HCT-CI)评分 0 的患者中,MAC 组的总生存(OS)优于 RIC 组(P=0.008),而在 HCT-CI 评分≥3 的患者中,RIC 组的 OS 优于 MAC 组(P=0.029)。根据预处理方案的类型,基于 12Gy 全身照射的 MAC 方案在 OS 和 CRFS 方面优于其他 MAC 方案,与 RIC 方案的结果相当。总之,除了 MAC 方案外,RIC 和 NMAC 方案也是 MDS-Lo 患者的有前途的选择。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验